Phase III Trial For Sanofi Anti-Clotting Drug Halted Due To Excess Bleeding

Sanofi-Aventis’ idraparinux demonstrated noninferiority versus vitamin K antagonists but was associated with more bleeding, according to Lancet article.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet